科前生物
(688526)
| 流通市值：83.67亿 | | | 总市值：83.67亿 |
| 流通股本：4.66亿 | | | 总股本：4.66亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 487,290,650.57 | 245,188,828.52 | 941,923,862.86 | 665,506,663.22 |
| 营业收入 | 487,290,650.57 | 245,188,828.52 | 941,923,862.86 | 665,506,663.22 |
| 二、营业总成本 | 257,541,676.39 | 133,324,710.25 | 547,793,468.42 | 393,227,605.15 |
| 营业成本 | 159,428,789.3 | 83,667,726.68 | 341,394,102.64 | 239,543,620.7 |
| 税金及附加 | 3,226,287.12 | 1,624,952.64 | 6,175,244.01 | 4,425,630.06 |
| 销售费用 | 51,325,590.19 | 27,319,280.7 | 114,045,783.13 | 93,026,235.06 |
| 管理费用 | 29,219,952.79 | 14,372,200.88 | 61,639,233.33 | 41,088,599.54 |
| 研发费用 | 45,497,479.23 | 21,330,798.19 | 86,121,440.39 | 61,152,604.48 |
| 财务费用 | -31,156,422.24 | -14,990,248.84 | -61,582,335.08 | -46,009,084.69 |
| 其中:利息费用 | 147,328.99 | 75,256.86 | 4,769,834.14 | 4,553,324.05 |
| 其中:利息收入 | 31,413,860.49 | 15,099,461.19 | 66,557,040.92 | 50,740,386.7 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 13,267,119.68 | 4,637,893.94 | 30,986,081.97 | 17,180,358.45 |
| 加:投资收益 | 3,572,559.49 | 1,485,275.25 | 6,616,220.42 | 11,262,998.83 |
| 资产处置收益 | 0 | - | 926,906.06 | 926,906.06 |
| 资产减值损失(新) | -671,363.37 | -4,320,266.79 | -16,080,317.97 | -17,299,862.03 |
| 信用减值损失(新) | 885,962.71 | 9,056,930.53 | -12,387,446.79 | -7,057,566.43 |
| 其他收益 | 6,939,358.55 | 2,949,688.73 | 34,655,817.28 | 20,216,362.37 |
| 四、营业利润 | 253,742,611.24 | 125,673,639.93 | 438,847,655.41 | 297,508,255.32 |
| 加:营业外收入 | 97,257.97 | 47,370.4 | 167,637.96 | 93,582.98 |
| 减:营业外支出 | 264,961.24 | 225,959.33 | 882,440.48 | 790,205.91 |
| 五、利润总额 | 253,574,907.97 | 125,495,051 | 438,132,852.89 | 296,811,632.39 |
| 减:所得税费用 | 34,297,146.77 | 17,708,778.25 | 56,643,206.58 | 36,804,185.17 |
| 六、净利润 | 219,277,761.2 | 107,786,272.75 | 381,489,646.31 | 260,007,447.22 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 219,277,761.2 | 107,786,272.75 | 381,489,646.31 | 260,007,447.22 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 219,896,297.5 | 108,236,874.48 | 382,350,180.06 | 260,600,917.75 |
| 少数股东损益 | -618,536.3 | -450,601.73 | -860,533.75 | -593,470.53 |
| 扣除非经常损益后的净利润 | 189,959,243.54 | 91,609,574.49 | 311,886,194.33 | 223,775,470.14 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.47 | 0.23 | 0.82 | 0.56 |
| (二)稀释每股收益 | 0.47 | 0.23 | 0.82 | 0.56 |
| 八、其他综合收益 | 50,736,402.83 | 15,356,455.6 | -42,473,821.86 | -7,555,091.9 |
| 归属于母公司股东的其他综合收益 | 50,736,402.83 | 15,356,455.6 | -42,473,821.86 | -7,555,091.9 |
| 九、综合收益总额 | 270,014,164.03 | 123,142,728.35 | 339,015,824.45 | 252,452,355.32 |
| 归属于母公司股东的综合收益总额 | 270,632,700.33 | 123,593,330.08 | 339,876,358.2 | 253,045,825.85 |
| 归属于少数股东的综合收益总额 | -618,536.3 | -450,601.73 | -860,533.75 | -593,470.53 |
| 公告日期 | 2025-08-26 | 2025-04-29 | 2025-04-29 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |